One drug blocks mTOR signaling, and the other stops the blocker from acting anywhere in the body but the brain, lowering the potential for side effects.

Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.

Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.

Oxytocin therapies have failed to consistently benefit autistic people, but their effects in people with two autism-linked conditions may yield new insights, experts argue.

The drug quells seizures in children with Dravet syndrome or Lennox-Gastaut syndrome.

The field of ABA needs more compassion and individualization.

Prenatal exposure to topiramate increases a child’s autism odds, according to the study that prompted the inquiry, but experts caution that pregnant people with epilepsy have few other options for controlling seizures.

Roche’s gene therapy drug Rugonersen boosts expression of the protein missing in the syndrome in mice and monkeys, but whether it works in people remains to be seen.

Interventions that moderate a need for ‘sameness’ may prevent anxiety traits.

Interim results from the previously paused trial suggest that doses of the experimental gene therapy drug GTX-102 are well tolerated in children with the autism-linked condition.